Compare NOM & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NOM | BOLD |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 26.9M |
| IPO Year | N/A | 2024 |
| Metric | NOM | BOLD |
|---|---|---|
| Price | $11.35 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 6.9K | ★ 125.4K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $1.00 |
| 52 Week High | $10.48 | $2.77 |
| Indicator | NOM | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 63.57 |
| Support Level | $11.00 | $1.14 |
| Resistance Level | $12.00 | $1.24 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 21.85 | 76.24 |
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.